REPORT ID 4529

EMEA (Europe, Middle East and Africa) Bioengineered Protein Drugs Market Report 2017

Publish Date
18-Dec-17
Pages
115
Format
Electronic (PDF)

In this report, the EMEA Bioengineered Protein Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of Bioengineered Protein Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Bioengineered Protein Drugs market competition by top manufacturers/players, with Bioengineered Protein Drugs sales volume (MT), price (USD/Kg), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Abbott Laboratories
    F. Hoffmann-La Roche Ltd
    Amgen, Inc.
    Bayer AG
    Merck & Co., Inc.
    Dr. Reddy?s Laboratories Ltd.
    Biocon Ltd.
    Eli Lilly and Company
    Sanofi
    GlaxoSmithKline plc
    Johnson & Johnson
    JanssenNovartis AG
    Panacea Biotec
    ProBioGen AG

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Therapeutic Proteins
    Monoclonal Antibodies
    Vaccines

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Diabetes and Hormonal Disorders
    Genetic and Fertility Disorders
    Cancers
    Organ Transplants
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Bioengineered Protein Drugs Market Report 2017
1 Bioengineered Protein Drugs Overview
    1.1 Product Overview and Scope of Bioengineered Protein Drugs
    1.2 Classification of Bioengineered Protein Drugs
        1.2.1 EMEA Bioengineered Protein Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Bioengineered Protein Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Therapeutic Proteins
        1.2.4 Monoclonal Antibodies
        1.2.5 Vaccines
    1.3 EMEA Bioengineered Protein Drugs Market by Application/End Users
        1.3.1 EMEA Bioengineered Protein Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Diabetes and Hormonal Disorders
        1.3.3 Genetic and Fertility Disorders
        1.3.4 Cancers
        1.3.5 Organ Transplants
        1.3.6 Others
    1.4 EMEA Bioengineered Protein Drugs Market by Region
        1.4.1 EMEA Bioengineered Protein Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Bioengineered Protein Drugs (2012-2022)
        1.5.1 EMEA Bioengineered Protein Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Bioengineered Protein Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Bioengineered Protein Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Bioengineered Protein Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Bioengineered Protein Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Bioengineered Protein Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Bioengineered Protein Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Bioengineered Protein Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Bioengineered Protein Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Bioengineered Protein Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Bioengineered Protein Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Bioengineered Protein Drugs (Volume) by Application
    2.4 EMEA Bioengineered Protein Drugs (Volume and Value) by Region
        2.4.1 EMEA Bioengineered Protein Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Bioengineered Protein Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Bioengineered Protein Drugs Sales Price by Region (2012-2017)

3 Europe Bioengineered Protein Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Bioengineered Protein Drugs Sales and Value (2012-2017)
        3.1.1 Europe Bioengineered Protein Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Bioengineered Protein Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Bioengineered Protein Drugs Sales and Market Share by Type
    3.3 Europe Bioengineered Protein Drugs Sales and Market Share by Application
    3.4 Europe Bioengineered Protein Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Bioengineered Protein Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Bioengineered Protein Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)

4 Middle East Bioengineered Protein Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Bioengineered Protein Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Bioengineered Protein Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Bioengineered Protein Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Bioengineered Protein Drugs Sales and Market Share by Type
    4.3 Middle East Bioengineered Protein Drugs Sales and Market Share by Application
    4.4 Middle East Bioengineered Protein Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Bioengineered Protein Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Bioengineered Protein Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)

5 Africa Bioengineered Protein Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Bioengineered Protein Drugs Sales and Value (2012-2017)
        5.1.1 Africa Bioengineered Protein Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Bioengineered Protein Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Bioengineered Protein Drugs Sales and Market Share by Type
    5.3 Africa Bioengineered Protein Drugs Sales and Market Share by Application
    5.4 Africa Bioengineered Protein Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Bioengineered Protein Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Bioengineered Protein Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Bioengineered Protein Drugs Sales and Growth Rate (2012-2017)

6 EMEA Bioengineered Protein Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Abbott Laboratories
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Abbott Laboratories Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 F. Hoffmann-La Roche Ltd
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 F. Hoffmann-La Roche Ltd Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Amgen, Inc.
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Amgen, Inc. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Bayer AG
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Bayer AG Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Merck & Co., Inc.
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Merck & Co., Inc. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Dr. Reddy?s Laboratories Ltd.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Dr. Reddy?s Laboratories Ltd. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Biocon Ltd.
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Biocon Ltd. Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Eli Lilly and Company
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Eli Lilly and Company Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Sanofi
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sanofi Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 GlaxoSmithKline plc
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Bioengineered Protein Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 GlaxoSmithKline plc Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Johnson & Johnson
    6.12 JanssenNovartis AG
    6.13 Panacea Biotec
    6.14 ProBioGen AG

7 Bioengineered Protein Drugs Manufacturing Cost Analysis
    7.1 Bioengineered Protein Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Bioengineered Protein Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Bioengineered Protein Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Bioengineered Protein Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Bioengineered Protein Drugs Market Forecast (2017-2022)
    11.1 EMEA Bioengineered Protein Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Bioengineered Protein Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Bioengineered Protein Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Bioengineered Protein Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Bioengineered Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Bioengineered Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Bioengineered Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Bioengineered Protein Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Bioengineered Protein Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Bioengineered Protein Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer